The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Increased capability to produce medicines for challenging diseases including cancer
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Subscribe To Our Newsletter & Stay Updated
